Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials

BACKGROUND AND AIM: Hepatorenal syndrome (HRS) is a fatal complication of liver cirrhosis with a limited pharmacological option. Terlipressin is a vasoconstrictor that is approved in many countries but not yet in the United States. This is a meta‐analysis of randomized controlled trials (RCTs) to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mohamed M G, Rauf, Abdul, Adam, Abubakr, Kheiri, Babikir, Lacasse, Alexandre, El‐Halawany, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341180/
https://www.ncbi.nlm.nih.gov/pubmed/34386597
http://dx.doi.org/10.1002/jgh3.12600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341180/
https://www.ncbi.nlm.nih.gov/pubmed/34386597
http://dx.doi.org/10.1002/jgh3.12600

Ejemplares similares